Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway

The usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary heart disease in the general population remains unclear. In a nested case-control study in Norway, 1,488 incident myocardial infarctions were registered during 11.3 years of follow-up and...

Descripción completa

Detalles Bibliográficos
Autores principales: Laugsand, Lars E., Åsvold, Bjørn O., Vatten, Lars J., Janszky, Imre, Platou, Carl G., Michelsen, Annika E., Damås, Jan K., Aukrust, Pål, Ueland, Thor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
CLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113535/
https://www.ncbi.nlm.nih.gov/pubmed/30167541
http://dx.doi.org/10.1016/j.jacbts.2016.06.007
Descripción
Sumario:The usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary heart disease in the general population remains unclear. In a nested case-control study in Norway, 1,488 incident myocardial infarctions were registered during 11.3 years of follow-up and compared with 3,819 controls. Compared with participants in the lowest quartile of PCSK9, myocardial infarction risk was 47% higher in the highest quartile after adjustment for age and sex. After additional adjustment for low-density lipoprotein cholesterol, the association was strongly attenuated. Thus, circulating PCSK9 does not contribute useful information in the assessment of myocardial infarction risk in the general population beyond the information provided by lipid measurements.

Ejemplares similares